King Pharmaceuticals Acquiring U.S. Marketing and Distribution Rights To Altace
During 1994, the U.S. National Right to Life Committee announced an anti-RU-486 boycott, targeting all Hoechst pharmaceutical products including Altace. By September 17, the pro-life organization Pharmacists For Life International joined the NRLC anti-RU-486 boycott "...against the American subsidiary of Hoechst, AG Hoechst-Roussel, Hoechst-Celanese, its generic subsidiary Coply Pharmaceuticals and the agricultural Hoechst subsidiary" while asking U.S. consumers to "...focus on key Hoechst drugs which have the most economic impact rather than taking an across-the-board shotgun approach" and specifically targeting Altace as a boycott list item.
Hoechst merged with Marion Merrill Dow of Kansas City, Missouri in 1995, forming the Hoechst U.S. pharmaceutical subsidiary Hoechst Marion Roussel (HMR). Altace was bringing in under $90 million in U.S. revenues for HMR and Hoechst had stopped promoting Altace within the United States., and King Pharmaceuticals President Jefferson "Jeff" Gregory also began negotiations in 1995 with Hoechst to acquire U.S. distribution rights to Altace.
The King Pharmaceuticals wholly owned subsidiary Monarch Pharmaceuticals, Inc. (another brother of John Gregory - Joseph Gregory - was then the president of Monarch Pharmaceuticals) acquired ownership of the U.S. distribution and marketing rights to Altace and other Hoescht products from Hoescht AG subsidiary Hoechst Marion Roussel of Kansas City, Missouri on December 18, 1998, and following a January 1999 merger a few weeks later with Rhône-Poulenc, Hoechst assumed the new corporate identity of Aventis).
In 2001, Forbes magazine ranked John Gregory among the 400 richest Americans. The bulk of Gregory's personal fortune was due in large part due to the ability of King Pharmaceuticals, Inc. to reintroduce the Hoechst branded prescription drug Altace back into the U.S. market under the King Pharmaceuticals,Inc. subsidiary Monarch Pharmaceuticals brand following the 1998 U.S. marketing and distribution agreement between KingPharmaceuticals/Monarch and Hoechst/HMR.
In late December 1998, King Pharmaceuticals (d.b.a. Monarch Pharmaceuticals, Inc.) purchased the U.S. marketing and distribution rights of the company's most successful drug, Altace, for $362.5 million from the U.S. subsidiary of Hoechst AG, Hoechst Marion Roussel of Kansas City. As a result of increasing the number of sales representatives and the findings of the Heart Outcomes Prevention Evaluation (HOPE), Altace sales skyrocketed. Using profits from Altace, King continued to add product lines, the most significant purchases being Levoxyl, Thrombin, and Cytomel in 2000. Also in 2000, seeing fewer opportunities to obtain branded drugs, the company acquired an R&D company based in North Carolina. In 2002, King purchased a maker of auto-injectors, Meridian Medical Technologies.
In 2002, John Gregory stepped down as CEO, and his brother Jefferson Gregory took over. Then in 2004, Jeff Gregory stepped down as well after the SEC began investigations into King’s Medicaid billing practices. The board named Brian Markison to replace him. Soon after, in July 2004, a deal was made for Mylan Laboratories to acquire King for $4 billion. Investors, most notably Carl Icahn, were critical of the merger, saying that Mylan was overpaying for King. The next year the deal was called off.
In 2008 King Pharmaceuticals acquired Alpharma Pharmaceuticals to expand into the pain treatment market. From the acquisition, King gained the patents on the pain management drugs, Flector and Embeda.
Read more about this topic: King Pharmaceuticals
Famous quotes containing the words king, acquiring, distribution and/or rights:
“Upon Saint Crispin’s day
Fought was this noble fray,
Which fame did not delay
To England to carry.
On when shall Englishmen
With such acts fill a pen,
Or England breed again
Such a King Harry?”
—Michael Drayton (1563–1631)
“There are three principal means of acquiring knowledge available to us: observation of nature, reflection, and experimentation. Observation collects facts; reflection combines them; experimentation verifies the result of that combination. Our observation of nature must be diligent, our reflection profound, and our experiments exact. We rarely see these three means combined; and for this reason, creative geniuses are not common.”
—Denis Diderot (1713–1784)
“My topic for Army reunions ... this summer: How to prepare for war in time of peace. Not by fortifications, by navies, or by standing armies. But by policies which will add to the happiness and the comfort of all our people and which will tend to the distribution of intelligence [and] wealth equally among all. Our strength is a contented and intelligent community.”
—Rutherford Birchard Hayes (1822–1893)
“...at this stage in the advancement of women the best policy for them is not to talk much about the abstract principles of women’s rights but to do good work in any job they get, better work if possible than their male colleagues.”
—Virginia Crocheron Gildersleeve (1877–1965)